Tooru PLC trading update shows stronger EBITDA, rising revenue and better retail momentum
Tooru has put out a genuinely encouraging trading update. The headline is simple: the group says its operating subsidiaries delivered a strong EBITDA performance in 2025, and that momentum has carried into the first quarter of 2026.
For retail investors, that matters because this is not just another vague “we are pleased” statement. The company has actually given a current trading snapshot, saying its operating businesses generated monthly average gross revenue of around £1 million and EBITDA of £150,000 in Q1 2026. EBITDA means earnings before interest, tax, depreciation and amortisation – in plain English, a commonly used measure of underlying operating profit.
Key numbers from the Tooru PLC RNS
| Metric | Figure | What it tells investors |
|---|---|---|
| Q1 2026 monthly average gross revenue | Around £1 million | The group has a meaningful revenue base coming through each month |
| Q1 2026 monthly average EBITDA | £150,000 | Operations are producing positive earnings before finance and non-cash costs |
| Potential Mylky acquisition share issue price | 0.77 pence per share | The agreed transaction reference price is well above the current market price cited by the company |
| Current share price referenced in the RNS | 0.19 pence | Shows how weak the market valuation currently is |
What the Tooru trading update means for investors right now
The strongest part of this announcement is the combination of revenue growth and EBITDA generation. Plenty of small quoted consumer businesses can grow sales, but fewer manage to show positive operating earnings at the same time. Tooru is saying it is doing both.
There is also a useful detail in the wording. The board expects these levels to increase as OAF builds its market presence and Pulsin benefits from increased capital investment and distribution. That is not formal guidance, but it does signal confidence that Q1 was not a one-off blip.
The missing piece is that the company has not disclosed exact full-year 2025 revenue, EBITDA or profit figures in this update. So while the tone is positive, investors still need the audited or final numbers to judge the scale of improvement properly.
OAF and Juvela expansion into Asda and Tesco is the clearest growth driver
If you want the operational story in one sentence, it is this: OAF looks like the current growth engine. The brand has launched with Asda, and Tooru says initial sales are tracking ahead of expectations.
That is important because breaking into a major supermarket is one thing, but selling well enough to justify shelf space is another. Early traction in Asda suggests OAF is not just winning listings, it may also be winning customers.
The brand is also introducing new product lines into Tesco, including Softie Sub Rolls. More stock keeping units in a major chain usually means more visibility, more basket opportunities and a stronger chance of scaling quickly if sell-through holds up.
Juvela itself is described as performing as expected, which is steady rather than spectacular. There is nothing wrong with that. In a group like this, having one stable brand and one faster-growing brand can be a healthy mix.
The company also highlighted OAF’s attendance at the Allergy and Free From Show in Birmingham, saying it generated significant engagement from consumers and retail partners. That is not a financial metric, but for a health and wellness brand in the free-from space, awareness and retail interest can be very valuable early signals.
Pulsin returning to growth could be more important than it first appears
Pulsin’s update is easy to overlook, but I would not dismiss it. The company says the brand has returned to growth with increased margins after a period of consolidation and range optimisation.
That wording suggests Pulsin has been through a tidying-up phase, likely trimming or refining its offering rather than chasing poor-quality sales. If the business is now growing again with higher margins, that is a much better outcome than growth bought at weak profitability.
Tooru also says Pulsin has good shelf availability, fresh capital support and a new contract manufacturing arrangement in place. That sounds operationally significant. Better manufacturing arrangements can improve efficiency, reduce disruption and support margin recovery, although the company has not disclosed the exact financial benefit.
The potential Mylky acquisition could be transformative, but it is not done yet
The most interesting strategic point in the RNS is the proposed acquisition of Mylky. Tooru says it has signed terms and is exploring various debt funding structures to complete the deal, given Mylky’s “very strong cash generation characteristics”.
This tells us two things. First, the board clearly wants the deal and believes Mylky would add “significant scale and earnings capability” to the group. Second, funding is still being worked through, which means there is execution risk and the acquisition is not yet complete.
The share pricing point is striking. The transaction terms include issuing Tooru shares at 0.77 pence per share, while the company says the current market price is 0.19 pence. That is a huge gap, and the board is effectively arguing that the market is undervaluing the business.
That may be true, but investors should stay practical. A board saying the shares are worth more than the current price is not proof by itself. What matters is whether trading continues to improve and whether any acquisition is completed on sensible funding terms.
It is also worth noting what has not been disclosed. The RNS does not give the size of Mylky, the expected purchase price, the amount of debt being considered, or the timetable for completion. Those details will matter a lot.
What is positive and what is negative in this Tooru PLC update?
The positives
- Q1 2026 monthly average gross revenue of around £1 million and EBITDA of £150,000 show real operating momentum.
- OAF is expanding into major retailers, with Asda sales ahead of expectations and new Tesco product lines coming through.
- Pulsin has returned to growth and margins have improved.
- The board sees room for further growth from market presence, investment and distribution.
The negatives and watchpoints
- Exact 2025 financial figures are not disclosed in this trading update.
- The Mylky acquisition is still only potential, with funding structures under review.
- The share price referenced by the company, 0.19 pence, shows that the market remains sceptical.
- The board blames geopolitical turmoil for weak growth stock appetite, but investors will still want harder evidence in future numbers.
My view on the Tooru share story after this RNS
This is a good update. Not perfect, and not complete, but definitely good.
The reason I say that is because the message is backed by operating detail rather than just warm words. You have improving EBITDA, visible revenue, a growing retail footprint for OAF, and a recovery story at Pulsin. That gives the statement more substance than many AIM trading updates.
The acquisition angle adds potential upside, but I would treat that as optional rather than central for now. Until funding is confirmed and terms are fully disclosed, Mylky is an interesting possibility, not part of the investment case you can bank on today.
For existing shareholders, this RNS should be reassuring because it suggests the underlying business is moving in the right direction. For new investors, the next step is to watch for fuller financial disclosure and any concrete update on Mylky. If those also land well, this could start to look like a more credible small-cap recovery story rather than just a hopeful one.
